Elan settles DoJ marketing probe for $203M

Elan has come to terms with the U.S. Justice Department. In the latest whistleblower settlement, the Irish drugmaker agreed to pay $203 million and plead guilty to a misdemeanor violation of the Food, Drug & Cosmetic Act. The issue: Its marketing program for the epilepsy drug Zonegran.

According to the DoJ, Elan promoted Zonegran for a variety of off-label uses. The drug was FDA-approved as an adjunct treatment for epilepsy in people over 16 years of age, but it was a late entry into the market, facing competition from several other similar meds. Facing financial pressures, Elan scouted around for potential off-label sales of Zonegran, using misleading promotional information.

Among the off-label sales: mood stabilization, bipolar disorder, weight loss and pediatric use. The company paid "illegal kickbacks" to boost prescriptions as well, the DoJ states. The settlement deal includes a criminal fine of $97 million, $3.6 million in forfeited assets, and a $102 million civil settlement, the DoJ says in a statement.

"Elan deliberately chose to prioritize profit over its obligation to the FDA and consumers," U.S. Attorney Carmen Ortiz said in a statement. "Today's plea and sentencing should serve as a reminder to any company engaging in off-label marketing schemes, that the government is continuing to aggressively investigate and prosecute companies who intentionally put patient safety at risk in order to turn a profit."

- see the DoJ's release
- get more from UPI

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.